Last updated: 2026-09-16 10:30:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Zymeworks Inc. (ZYME) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $26.10, with a market capitalisation of $1.92B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $15.79 to $31.34. This page covers its latest market performance, valuation, price trends and company information.
$1.92B | |
$26.06 | |
$59.03 | |
$4.11 | |
$26.05 | |
93.00 | |
606.48K | |
-- | |
$31.34 | |
$15.79 | |
-- | |
-- |
Zymeworks Inc. (ZYME) is trading at $26.10 in pre-market trading as of 2026-09-16 08:32:00, up 0.19% ($0.05) from the previous close of $26.05
Pre-market trading shows how investors are pricing ZYME before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Zymeworks Inc. (ZYME) moved from $29.19 to $26.10, representing a decline of 10.59% ($3.09).
The stock traded between $25.81 and $29.99 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 599.31 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 66.3%
ZYME is currently trading at $26.10, placing it 66.3% of the way from its 52-week low of $15.79 to its 52-week high of $31.34. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 264 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Zymeworks Inc. (ZYME) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.